SCHEMBL7704932

SCHEMBL7704932

CC1Oc2ccc(CN(Cc3ccc(F)cc3)C(=O)OC(C)(C)C)cc2NC1=S

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
NCOR2 Q9Y618 1/20 0.35
KCNQ4 P56696 3/20 0.35
KCNQ5 Q9NR82 3/20 0.35
GRM2 Q14416 1/20 0.35
KDM1A O60341 2/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
PARP1 P09874 2/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
NR1D1 P20393 1/20 0.33
NR3C2 P08235 1/20 0.33
HTR2A P28223 1/20 0.32
ALOX15 P16050 1/20 0.32
HSD17B10 Q99714 1/20 0.32
SSTR4 P31391 1/20 0.32
RIPK1 Q13546 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7712797 0.92 RIPK1 (0.36) HDAC3HDAC1HDAC2NCOR2PARP1
SCHEMBL7704945 0.91 HDAC3 (0.44) HDAC3HDAC1HDAC2NCOR2PARP1
SCHEMBL7704907 0.91 HSD17B10 (0.38) HDAC3HDAC1HDAC2NCOR2PARP1
SCHEMBL7708363 0.90 TP53 (0.35) HDAC3HDAC1HDAC2NCOR2PARP1
SCHEMBL7711422 0.90 HSD17B10 (0.36) HDAC3HDAC1HDAC2NCOR2PARP1
SCHEMBL6309617 0.90 HDAC1 (0.43) HDAC3HDAC1HDAC2NCOR2PARP1
SCHEMBL7708149 0.89 PARP1 (0.45) HDAC3HDAC1HDAC2NCOR2KCNQ4
SCHEMBL7704942 0.89 ALDH1A1 (0.37) HDAC3HDAC1HDAC2NCOR2PARP1
SCHEMBL7711220 0.88 HDAC3 (0.34) HDAC3HDAC1HDAC2NCOR2PARP1
SCHEMBL6302990 0.87 PARP1 (0.38) HDAC3HDAC1HDAC2NCOR2PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed